Language: BG BG
← Back to results
Recruiting Not applicable NCT04740697

Study to Evaluate the Impact of the Use of Alternative and Complementary Therapies on Therapeutic Adherence in Patients Treated With taMoxifen for Early Stage Breast Cancer

No applicable phase (e.g. observational)
Conditions: Breast Cancer

Sponsor: Institut Claudius Regaud

trial.available_in: БГ
Overview
This is a pilot, prospective, interventional, monocentric study designed to evaluate, in a real-life situation, adherence to tamoxifen treatment as a function of the taking of alternative and complementary therapies in patients with localized hormone-dependent breast cancer. 200 patients will be included in the study. Each patient will be followed for one day.
Who can participate
Inclusion Criteria: 1. Age ≥ 18 years at entry into the study. 2. Patient treated for hormone-dependent localized breast cancer requiring adjuvant Hormonal Therapy (HT) with tamoxifen. 3. Patients treated with tamoxifen for a maximum of 1 to 3 years. 4. Patient affiliated with a Social Security system in France. 5. Patients who signed informed consent prior to inclusion in the study and prior to any specific study procedures. Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Any psychological, family, geographical or sociological condition that does not allow the medical follow-up and/or the procedures foreseen in the study protocol to be respected. 3. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice).
Interventions
Treatment requiring adjuvant Hormonal Therapy (HT) with tamoxifen.
OTHER
Locations 1
France (1)
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse
Technical details
Status
Recruiting
Phase
Not applicable
Study type
INTERVENTIONAL
Sex
Female only
Minimum age
18 Months
Healthy volunteers
No
Start date
12.02.2021
Completion date
01.02.2028
Registry ID
NCT04740697
Source
clinicaltrials.gov
trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.